Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of R130 in Relapsed/Refractory Ovarian Cancer
NCT05801783Phase 1Recruiting
- Sponsor
- Shanghai Yunying Medical Technology Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R130 in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Shanghai Yunying Medical Technology Co., Ltd. Primary endpoints: Adverse Events up to 6 months and Systemic immune response up to 6 months. Started Dec 2022; status: recruiting.
02
Drugs
R130
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05801783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05801783.